5-HT2C receptor mediation of unconditioned escape behaviour in the unstable elevated exposed plus maze

Psychopharmacology

Volumn 164, Issue 2, 2002, Pages 214-220

  Jones, Nicholas ^a   Duxon, Mark S ^b   King, Sheila M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT2C; Anxiety; Escape; m Chlorophenylpiperazine; Panic; Plus maze; Rat; SB 242084

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SODIUM CHLORIDE; 1-(3-CHLOROPHENYL)PIPERAZINE; AMINOPYRIDINE DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIORAL SCIENCE; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; ESCAPE BEHAVIOR; EXPLORATORY BEHAVIOR; FEAR; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; ANALYSIS OF VARIANCE; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; MOTOR ACTIVITY; PHYSIOLOGY; RANDOMIZATION; TIME;

AMINOPYRIDINES; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCAPE REACTION; EXPLORATORY BEHAVIOR; FEAR; INDOLES; MALE; MAZE LEARNING; MOTOR ACTIVITY; PIPERAZINES; RANDOM ALLOCATION; RATS; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TIME FACTORS;

EID: 0036836189     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-002-1197-9     Document Type: Article

References (45)

1. Benjamin J, Greenberg BD, Murphy DL (1996) Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psychopharmacology 127:140-149
2. Benjamin J, Geraci M, McCann U, Greenberg BD, Murphy DL (1999) Attenuated response to m-CPP and to pentagastrin after repeated m-CPP in panic disorder. Psychopharmacology 143:215-216
3. Bilkei-Gorzo A, Gyertyan I, Levay G (1998) mCPP-induced anxiety in the light-dark box in rats - A new method for screening anxiolytic activity. Psychopharmacology 139:291-298
4. Blanchard DC (1997) Stimulus and environmental control of defensive behaviors. In: Bouton M, Fanselow M (eds) The Functional Behaviorism of Robert C. Bolles: Learning, Motivation and Cognition. American Psychological Association, Washington DC, pp 283-305
5. Blanchard DC, Griebel G, Blanchard RJ (2001) Mouse defensive behaviors: Pharmacological and behavioral assays for anxiety and panic. Neurosci Biobehav Rev 25:205-218
6. 2C/2B receptor antagonists as potential anxiolytic agents: Synthesis, quantitative structure-activity relationships, and molecular modelling of substituted 1-(3-pyridylcar-bamoyl)indolines. J Med Chem 41:1598-1612
7. Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy subjects. Psycho-Pharmacology 92:14-24
8. 2C receptors. Neuropharmacology 39:1114-1117
9. Denboer JA, Westenberg HG (1990) Serotonin function in panic disorder: A double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102:85-94
10. 2C receptor responsiveness occurs on rearing rats in social isolation. Psychopharmacology 123:346-352
11. 2C receptors but not sympathomometic effects. Neuropharmacology 33:457-465
12. 2C receptor mode of action. Psychopharmacology 137:292-302
13. Graeff FG, Netto CF, Zangrossi H (1998) The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev 23:237-246
14. Grewal SS, Shepherd JK, Bill DJ, Fletcher A, Dourish CT (1997) Behavioural and pharmacological characterisation of the canopy stretch attend posture test as a model of anxiety in mice and rats. Psychopharmacology 133:29-38
15. 2 receptor subtype antagonists in rat and mouse models of anxiety. Neuropharmacology 36:793-802
16. 3 receptors. Psychopharmacology 97:489-495
17. 1C receptors in the serotonergic control of periaqueductal gray induced aversion in rats. Psychopharmacology 100:372-376
18. B receptor ligands in a validated simulation of panic anxiety in rats. Eur Neuropsychopharmacol 6:291-298
19. 2C receptors in affective disorders. Exp Opin Invest Drugs 7:1587-1599
20. 2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol 8:161-168
21. Jones N, King SM (2001) Influence of circadian phase and test illumination on pre-clinical models of anxiety. Physiol Behav 72:99-106
22. Jones N, Duxon MS, King SM (2002) Ethopharmacological analysis of the unstable elevated exposed plus maze, a novel model of extreme anxiety: Predictive validity and sensitivity to anxiogenic agents. Psychopharmacology 161:314-323
23. Kantor S, Anheuer ZE, Bagdy G (2000) High and low aggression in Fawn-Hooded rats. Physiol Behav 71:551-557
24. Kennedy AJ, Gibson EL, O'Connell MT, Curzon G (1993) Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP. Psychopharmacology 113:262-268
25. 1C receptor antagonists. Eur J Pharmacol 164:445-454
26. 2C/2B receptor antagonist. Br J Pharmacol 111:797-802
27. 2B receptor antagonist, in two conflict models of anxiety. Psychopharmacology 118:178-182
28. 2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol 117:427-434
29. 2C receptor antagonist. Neuropharmacology 36:609-620
30. 2C receptor agonist, in three animal models of anxiety. Eur J Pharmacol 387:197-204
31. King SM (1999a) Escape-related behaviours in an unstable elevated and exposed environment I. A new behavioural model of extreme anxiety. Behav Brain Res 98:113-126
32. King SM (1999b) Escape-related behaviours in an unstable elevated and exposed environment II. Long term sensitisation after repetitive electrical stimulation of the rodent midbrain defence system. Behav Brain Res 98:127-142
33. King SM (1999c) Maturational and gender differences in rodent escape strategies: Possible implications for preclinical models of anxiety. Psychobiology 27:513-520
34. 2C receptor antagonist. Soc Neurosci Abstr 26:1174
35. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (1991) Anxiogenic effects of m-CPP in patients with panic disorder: Comparison of caffeine's anxiogenic effects. Biol Psychiatry 30:973-984
36. 2C receptor agonists: Pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 286:913-924
37. Mellow AM, Lawlor BA, Sunderland T, Mueller EA, Molchan SE, Murphy DL (1990) Effects of daily oral m-chlorophenylpiperazine in elderly depressed patients. Initial experience with a serotonin agonist. Biol Psychiatry 28:588-594
38. 1 antagonists, CP154,526 and DMP695: A comparison to other classes of anxiolytic agent. Neuropsychopharmacology 25:585-600
39. 2C receptor subtypes in the two types of fear generated by the elevated T-maze. Pharmacol Biochem Behav 58:1051-1057
40. Rodgers RJ, Cole JC, Cobain MR, Daly P, Doran PJ, Eells JR, Wallis P (1992) Anxiogenic-like effects of fluzapine and eltoprazine in the mouse elevated plus-maze: Profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav Pharmacol 3:621-634
41. Rodgers RJ, Cole JC, Aboualfa K, Stephenson LH (1995) Ethopharmacological analysis of the effects of putative "anxiogenic" agents in the mouse elevated plus-maze. Pharmacol Biochem Behav 52:805-813
42. Saran A, Halaris A (1989) Panic attack precipitated by fluoxetine. J Neuropsychiatr Clin Neurosci 1:219-220
43. Sevy S, Brown S-L, Wetzler S, Kotler M, Molcho A, Plutchick R, van Praag HM (1994) Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. Psychiatry Res 53:219-229
44. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT (1994) Behavioural and pharmacological characterisation of the elevated "zero maze" as an animal model of anxiety. Psychopharmacology 116:56-64
45. Southwick SM, Krystal JH, Bremner JD, Morgan CA III, Nicolaou AL, Nagy LM, Johnson DR, Heninger GR, Charney DS (1997) Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry 54:749-758